October 3rd 2024
Acalabrutinib, a BTK inhibitor, has shown promising results in treating mantle cell lymphoma, with the FDA granting it priority review.
September 20th 2024
September 19th 2024
September 18th 2024
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Data Support Momelotinib as a Differentiated Approach to Treating Myelofibrosis
January 22nd 2021JAK inhibitors designed for the treatment of myelofibrosis address the splenic response and constitutional symptoms associated with the disease, but the agents are inherently myelosuppressive and can exacerbate anemia and thrombocytopenia.
Read More
Younger Patients, Select Subsets in AML May Have Higher Chances of Long-Term Survival
January 9th 2021Ten-year overall survival is low among patients with acute myeloid leukemia , but an analysis demonstrated that survival is shorter for older patients treated with chemotherapy alone, according to published findings.
Read More
Sabatolimab Demonstrates Promising Efficacy in Acute Myeloid Leukemia, Myelodysplastic Syndrome
January 2nd 2021In a phase 1b clinical trial presented during the 2020 American Society of Hematology Annual Meeting, investigators sought to determine the efficacy and safety of the novel TIM-3–targeting IgG4 antibody sabatolimab in combination with hypomethylating agents as treatment of patients with acute myeloid leukemia, as well as high-risk myelodysplastic syndrome.
Read More
CAR T-Cell Therapies Are Set to Expand Into More Hematologic Malignancy Indications
December 26th 2020Multiple chimeric antigen receptor T-cell therapies for the treatment of lymphomas and multiple myeloma have moved forward in the regulatory process, with 1 new FDA approval in 2020 and others anticipated in the near future.
Read More
Pevonedistat/Azacitidine Combo Demonstrates Encouraging EFS Data in Phase 2 Trial in MDS
December 24th 2020Justin M. Watts, MD, discusses the key takeaway from the phase 2 Study P-2001 clinical trial, a randomized study comparing the safety and efficacy of pevonedistat in combination with azacitidine in patients with high-risk myelodysplastic syndromes.
Watch
FDA Updates Prescribing Label for Ibrutinib for Waldenström Macroglobulinemia Indication
December 23rd 2020The FDA updated the prescribing label for the approval of ibrutinib to include efficacy and safety data as combination therapy with rituximab as treatment of patients with Waldenström’s macroglobulinemia.
Read More
CD123-Targeting ADC IMGN632 Demonstrates Encouraging Findings in Rare Blood Cancer
December 23rd 2020The novel CD123-targeting antibody-drug conjugate IMGN632 demonstrated promising clinical activity in a cohort of heavily pretreated patients with relapsed/refractory blastic plasmacytoid dendritic cell neoplasm and had a favorable tolerability.
Read More
Treating Transplant-Ineligible MM: Implications of the PEGASUS Study
December 23rd 2020Hematologist Rafael Fonseca comments on data demonstrated by the PEGASUS study in transplant-ineligible multiple myeloma and expectations for treating appropriate patients with the combination of daratumumab, lenalidomide, and dexamethasone vs other options moving forward.
Watch